FDA 483 - Lux Therapeutics LLC - May 12, 2023

During an inspection conducted by the U.S. Food and Drug Administration (FDA) from May 8-12, 2023, Lux Therapeutics LLC, a biological drug manufacturer located in Brookhaven, GA, received a Form FDA 483 citing significant observations. The inspection revealed several issues indicating a lack of adherence to regulatory requirements for drug manufacturing.

Specifically, the firm's quality control unit lacked written procedures for the receipt of white labeled products, failing to document essential checks like temperature, packaging, and labeling conditions upon arrival. Furthermore, the facility demonstrated inadequate separation between quarantined and distributed drug products, storing them together in the same freezer, raising concerns about potential mix-ups and contamination. Finally, Lux Therapeutics LLC did not follow its own written distribution procedures, as they failed to specify methods for monitoring product storage conditions during transportation.

These observations highlight deficiencies in quality control, facility segregation, and adherence to established distribution protocols, which are crucial for ensuring product quality and patient safety within the regulatory framework governing biological drug manufacturing. The company is expected to address these findings by implementing comprehensive corrective actions to ensure compliance and prevent recurrence.